LITM - EBS KOD and BORR among pre market gainers
Indaptus Therapeutics (INDP) +22% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors. Zealand Pharma (ZEAL) +19% announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism. CBAK Energy Technology (CBAT) +19% on Q1 results. SIGA Technologies (SIGA) +12% receives approval from the FDA for intravenous formulation of TPOXX® (tecovirimat). Snow Lake Resources (LITM) +12% announces significant findings from first drilling tests. Canaan (CAN) +11% on Q1 results. Canada Goose Holdings (GOOS) +10% on FQ4 results. Emergent BioSolutions (EBS) +11%. Kodiak Sciences (KOD) +10% grand opening of Kodiak Sciences' purpose-built bioconjugation facility to support potential commercial manufacture of KSI-301, an antibody biopolymer conjugate for retinal diseases. Broadway Financial Corporation (BYFC) +9%. Grab Holdings (GRAB) +8% on Q1 results. Borr Drilling (BORR) +5%. BJ's Wholesale Club Holdings (BJ) +6% on Q1 results.
For further details see:
EBS, KOD and BORR among pre market gainers